China’s Covid-19 Vaccine Has 100% Critical Illness Protection
According to data from the National Health Commission, as of October 13, 2021, 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps have reported a total of 222.5504 million doses of COVID-19 vaccine.
On September 24, the international vaccine field journal “Vaccine” published online entitled “An Observer Blind Method for the Effectiveness, Safety and Immunogenicity of a COVID-19 Virus Inactivated Vaccine for Healthy Adults Aged 18-59 Years Old” , Randomized, placebo-controlled Phase III clinical study: Interim analysis in Indonesia (A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia) research papers.
The results showed that the inactivated COVID-19 vaccine Kerlaifu developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd., is safe, effective, and the quality of the vaccine is stable.
A total of 1620 subjects were enrolled in this study, and they were randomly assigned to the vaccine group or placebo group at a ratio of 1:1, and were vaccinated with Kexing’s COVID-19 inactivated vaccine Kerlai at an interval of 14 days (emergency procedure). Fu or placebo, after vaccination, observe the safety, immunogenicity, and protective effect of symptomatic infection of the COVID-19 virus at least 14 days after the second dose of vaccination.
The safety results showed that the adverse events were mainly mild after inoculation with Kerrlive. Pain at the inoculation site and myalgia were the most common local or systemic adverse events, respectively.
The effectiveness results showed that the effectiveness of the second dose of Kellyford 14 days after vaccination was 65.3%, and the vaccine’s protective effect on hospitalization, severe illness, and death was 100%.
The immunogenicity results showed that 14 days after the second dose of vaccine, the seroconversion rate of specific immunoglobulin G (IgG) was 97.48%, which was significantly higher than the placebo group (0.75%); the neutralizing antibody positive conversion rate was 87.15 %, there was no positive transfer of neutralizing antibody in the placebo group.
In order to evaluate whether the quality of different batches of Kellyford is consistent, this study conducted serological studies on three batches of Kellyford recipients with batch numbers 20200308 and 2020041220200419.
The results of the study showed that there was no significant difference in the specific IgG positive rate 14 days after the second dose of Kraft in each batch, and the neutralizing antibody GMT of all batches increased by 7-8 times.
The results of this interim analysis show that Kellyford has good safety and immunogenicity, as well as good batch-to-batch consistency. The “emergency procedure” (2 doses of vaccine at an interval of 14 days) may be suitable for vaccination during a pandemic plan.
As of October 10, over 100 million people in Indonesia have been vaccinated against COVID-19, and the number of new confirmed cases and deaths in a single day has set the lowest record since the end of June last year.
In related news, at 9 am on October 12, a new batch of 2 million doses of the Coxing COVID-19 vaccine provided by China to Myanmar was delivered to Myanmar on two flights on the 13th and October 14.
So far, China has provided 5.9 million doses of COVID-19 vaccine to Myanmar.
As of October 3, the cumulative global supply of Coxing COVID-19 vaccine has reached 2 billion doses, and the cumulative inoculation is 1.6 billion doses. It is currently the world’s and China’s largest supply and use of COVID-19 vaccine, and the largest export volume of China’s COVID-19 vaccine. -19 vaccine.
